Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment

Impact · against what's priced in

The publication of Alamar's NULISAseq CNS 120 panel results in The Lancet Neurology provides external validation of the company's ability to track complex treatment responses in Alzheimer's patients. This evidence of utility for pharmaceutical companion diagnostics supports potential revenue growth for FY2027.

ALMR+0.60

No priced-in read yet